Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin Combined With Pucotenlimab for Neoadjuvant and Adjuvant Treatment of Locally Recurrent Resectable HNSCC
NCT07632339Phase 2Recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 2 trial of becotatug vedotin, pucotenlimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Shanghai Ninth People's Hospital. Started Jun 2026; status: recruiting.
02
Drugs
becotatug vedotinpucotenlimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07632339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07632339.